Skip to content
lifestyle.thedailyhaze.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
X4 Pharmaceuticals
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 21, 2026
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
April 29, 2026
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
March 4, 2026
←
Previous Page
1
2